Primcyv (Palbociclib) Capsule

Generic brands for Palbociclib Capsule Available in India Brand Name Primcyv Generic Name Palbociclib Strength 75mg, 100mg, 125mg Manufacturer Dr Reddy’s Laboratories Ltd  

Description

Description

This page contains brief details about the drug palbociclib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Palbociclib is an anticancer medication that was developed by Pfizer for treating breast cancer in postmenopausal women who tested positive for hormone receptors. It was initially approved in 2015 and later approved for treating metastatic breast cancer. Recently this medication has received a nod for its use in treating male breast cancer.

Mechanism of Action of Palbociclib

Palbociclib capsule produces its action by blocking the signal pathways of cyclin-dependent kinase 4 and 6 kinase enzymes involved in cancer cell proliferation. This medication inhibits cell division by attacking the cell division at the G phase to the S phase of the cell cycle.

Uses of Palbociclib

Palbociclib is used in the treatment of hormone-positive breast cancer. It is usually administered in combination with other hormonal therapy agents. Palbociclib is effective in treating breast cancer that has spread to other organs.

Palbociclib Dosage available

Palbociclib is intended for oral use only. It is often given along with other hormonal therapy agents. It must be consumed with meals and do not open/break the capsule. Palbociclib capsule is available in three different strengths 75mg capsule, 100 mg, and 125 mg capsules.

We can ship to :

News/Updates

References

  1. Pfizer Limited, Electronic medicines compendium (emc), [Revised on June 2021] [ Accessed on 26 Nov 2022], https://www.medicines.org.uk/emc/files/pil.4449.pdf
  2. Pfizer Labs, US Food and Drug Administration, [Revised on March 2017] [ Accessed on 26 Nov 2022], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf
  3. Neha S Mangini et al; Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer; The Annals of Pharmacotherapy; Published on Nov 2015; Accessed on 26/11/2022; https://pubmed.ncbi.nlm.nih.gov/26324355/
  4. Palbace; Pfizer; Revised on Oct 2021; Accessed on 26/11/2022; https://labeling.pfizer.com/ShowLabeling.aspx?id=14029